Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly spike protein messenger RNA (mRNA) vaccines, to date have yielded a high degree of efficacy against symptomatic infection and severe 2]. However, outcomes of patients with active hematologic malignancies are not well described, and remain a significant concern given data demonstrating poorer outcomes in sub-groups of these patients who become infected [3]; for example, a recent study of patients with chronic lymphocytic leukemia (CLL) demonstrated reduced antibody seroprevalence after vaccination in patients on active therapy with Burton Tyrosine Kinase (BTK) inhibitors [4]. These observations prompted us to evaluate post-vaccination antibody response in patients with Philadelphia-chromosome positive and negative Myeloproliferative Neoplasms (MPNs), including untreated patients and patients on active therapy.We evaluated antibody response in 74 consecutive patients with MPNs subsequent to two doses of the mRNA BNT162b2 (Pfizer) or mRNA-1273 (Moderna) vaccines, as per the U.S. Food and Drug Administration Emergency Use Authorization (EUA). We included patients with chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), or blastphase MPN (MPN-BP). Serology testing was performed as part of routine clinical practice using the AdviseDx SARS-CoV-2 IgG II reagent assay (Abbott Diagnostics). A result was considered positive with ≥50 AU/mL. The study was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center.Data were collected from a period spanning from April 2021 to September 2021, from 74 patients in total. The cohort consisted of 22 patients with CML, 14 patients with ET, 14 patients with PV, 22 patients with MF, and 2 patients with MPN-BP (both transformed from prior post-ET Myelofibrosis). The median age of included subjects was 68.2 years. Eighteen CML patients were receiving active treatment with ABL kinase inhibitors, including dasatinib
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.